Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Long-term use of glucocorticoids (GCs) causes numerous adverse effects, including glucose/lipid abnormalities, osteoporosis, and muscle wasting. The pathogenic mechanism, however, is not completely understood. In this study, we used plasminogen activator inhibitor-1 (PAI-1)–deficient mice to explore the role of PAI-1 in GC-induced glucose/lipid abnormalities, osteoporosis, and muscle wasting. Corticosterone markedly increased the levels of circulating PAI-1 and the PAI-1 mRNA level in the white adipose tissue of wild-type mice. PAI-1 deficiency significantly reduced insulin resistance and glucose intolerance but not hyperlipidemia induced by GC. An in vitro experiment revealed that active PAI-1 treatment inhibits insulin-induced phosphorylation of Akt and glucose uptake in HepG2 hepatocytes. However, this was not observed in 3T3-L1 adipocytes and C2C12 myotubes, indicating that PAI-1 suppressed insulin signaling in hepatocytes. PAI-1 deficiency attenuated the GC-induced bone loss presumably via inhibition of apoptosis of osteoblasts. Moreover, the PAI-1 deficiency also protected from GC-induced muscle loss. In conclusion, the current study indicated that PAI-1 is involved in GC-induced glucose metabolism abnormality, osteopenia, and muscle wasting in mice. PAI-1 may be a novel therapeutic target to mitigate the adverse effects of GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“Glucocorticoids (GCs) have strong anti-inflammatory properties and are highly effective in the treatment of allergies and inflammatory and autoimmune conditions, such as rheumatoid arthritis, asthma, inflammatory bowel disease, and collagen diseases (1,2).”
BackgroundEndocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554 · cited 1×
“Recent studies suggest that osteoblast-derived OCN, a bone matrix protein, is a potent regulator of glucose metabolism, acting by modulating the insulin release and peripheral insulin sensitivity (37,38).”
BackgroundMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Ferron, M., Hinoi, E., Karsenty, G., & Ducy, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711119105 · Cited by 900
Van Raalte, D. H., Ouwens, D. M., & Diamant, M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02067.x · Cited by 439
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Jia, D., O’Brien, C. A., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2006) · Endocrinology · doi:10.1210/en.2006-0459 · Cited by 394 · cited 1×
“During the initial stage of highdose GC therapy, a rapid but transient increase in bone resorption caused by increase in osteoclast number and activity can be observed in humans and in animal models (39,40).”
BackgroundGlucocorticoids suppress bone formation via the osteoclast.
Kim, H.-J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28084 · Cited by 384 · cited 1×
“Furthermore, GC suppresses the formation of osteoclast precursors (41,42).”
BackgroundGlucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168 · cited 7×
“Long-term GC treatment causes bone loss mainly due to the impaired osteoblastic bone formation (4).”
BackgroundInfluentialOptimized glucocorticoid therapy: teaching old drugs new tricks
Strehl, C., & Buttgereit, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.026 · Cited by 118
Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity
Darmon, P., Dadoun, F., Boullu-Ciocca, S., Grino, M., Alessi, M.-C., & Dutour, A. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00654.2005 · Cited by 59
Cited by
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Zhang, X., Tian, L., Majumdar, A., & Scheller, E. L. (2024) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2024.tb00300.x · Cited by 18
Metadata
- Authors
- Tamura, Y., Kawao, N., Yano, M., Okada, K., Okumoto, K., Chiba, Y., Matsuo, O., & Kaji, H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-12-31
- Volume
- 64
- Issue
- 6
- Pages
- 2194-2206
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2122987234
- Cited by
- 73
- References
- 10
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice. https://app.cochat.ai/papers/10.2337/db14-1192
- The paper
- Tamura, Y., Kawao, N., Yano, M., Okada, K., Okumoto, K., Chiba, Y., Matsuo, O., & Kaji, H. (2015). Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice. Diabetes. https://doi.org/10.2337/db14-1192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.